Economics and Preventing Hospital-Acquired Infection by Graves, Nicholas
The economics of preventing hospital-acquired infec-
tions is most often described in general terms. The under-
lying concepts and mechanisms are rarely made explicit
but should be understood for research and policy-making.
We define the key economic concepts and specify an illus-
trative model that uses hypothetical data to identify how two
related questions might be addressed: 1) how much should
be invested for infection control, and 2) what are the most
appropriate infection-control programs? We aim to make
explicit the economics of preventing hospital-acquired
infections.
Approximately 1 in 10 hospitalized patients will acquirean infection after admission, which results in substan-
tial economic cost (1). The primary cost is that patients with
hospital-acquired infections have their stay prolonged, dur-
ing which time they occupy scarce bed-days and require
additional diagnostic and therapeutic interventions (2).
Estimates of the cost of these infections, in 2002 prices,
suggest that the annual economic costs are $6.7 billion per
year in the United States (3)1 and £1.06 billion (approxi-
mately US $1.7 billion) in the United Kingdom (4).
The economic rationale for preventing hospital-
acquired infections has been discussed (5,6) and can be
summarized as follows: hospital-acquired infections take
up scarce health sector resources by prolonging patients’
hospital stay; effective infection-control strategies release
these resources for alternative uses. If these resources have
a value in an alternative use, then the infection control pro-
grams can be credited with generating cost savings; these
infection control programs are costly themselves, so the
expense of infection control should be compared to the
savings.
For many hospital infections, the costs of prevention are
likely to be lower than the value of the resources released
(4,7,8), even when costs “are estimated liberally and the
benefits presented conservatively” (9). Under these circum-
stances, infection control should be pursued, since more
stands to be gained than lost (5). We attempt to make
explicit the concepts on which these arguments rely and, in
particular, concentrate on providing a framework for
answering two questions: how much in total should we
invest in prevention for any given infection-control situa-
tion, and how should this investment be allocated among
competing infection-control strategies? Our aim is to make
the economics of prevention explicit while using a mini-
mum of technical language, algebra, and economics jargon.
Concepts and Definitions
Valuing Resources Attributable to 
Hospital-acquired Infection
Infection uses hospital resources. By preventing infec-
tion, these resources are saved. For some of these
resources, the associated expenditures may be terminated,
and the savings would be expressed in terms of cash-sav-
ings, for example saving on drugs, consumables, and
nursing staff employed on a contract that can be terminat-
ed at short notice. However, expenditures associated with
many resources are difficult to avoid in the short term, and
conserved resources cannot be easily, or costlessly,
exchanged for cash. A longer-term obligation to the
resource may exist due to a contractual commitment, such
as an employment contract with a staff member or a lease
agreement for a diagnostic device, or a physical commit-
ment, such as investment in buildings, capital equipment,
and infrastructure.
These differences illustrate the differences between
fixed and variable costs. While cash-savings from avoided
variable costs are easy to quantify, the resources that rep-
resent fixed costs cannot be exchanged for cash in the
short-term. Researchers have found that 84% (10) and
89% (4) of the costs of hospital care are fixed in the short
term. Furthermore, expenditures made to acquire fixed
resources, recorded by cost-accountants, may or may not
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1Care should be taken in interpreting this estimate, as it was
derived from data gathered in the mid-1970s (Study on the
Efficacy of Nosocomial Infection Control–SENIC).
be an accurate assessment of their economic value.
Because financial expenditures on fixed costs are unavoid-
able in the short-term, they are largely irrelevant to deci-
sion-making in the short-term. For economic analysis, we
prefer to explore the value of the best alternative use of the
resources that are fixed in the cost structure of the hospi-
tal. This value is the opportunity cost of the resource.
Perspective for Economic Evaluation
Many have argued that the benefits of infection control
are widespread. Treating infection represents an economic
burden to the hospital, and prevention saves these costs
(4,11–20); however, less is known about other benefits.
One reason might be that hospital administrators, who hold
the purse strings for infection control, are primarily inter-
ested in savings to their budgets and do not focus on other
benefits that might arise for patients, informal caregivers,
or other healthcare agencies (20). A broader perspective
might include the monetary value of avoided illness and
death from hospital infection. Attributing excess illness
and death to hospital infection, however, is difficult, and
accurately valuing these very real costs is fraught with
problems. Still, when a narrow perspective is adopted, and
costs and benefits other than those that fall directly on the
hospital sector are excluded, economic analyses may
underestimate the social benefits of infection-control pro-
grams.
Incremental and Marginal Analyses
Incremental and marginal analyses are concerned with
changes to “cost” and “benefit” in respect to the status quo
(existing hospital expenditures and their outcomes) (21). If
the existing budget for infection control is $100,000 and a
new infection-control program costs $40,000, the total cost
of infection control will increase to $140,000. The incre-
mental cost of the new program is the change in total cost
from $100,000 to $140,000, or $40,000. If implementing
this program avoids 50 bloodstream infections, then the
incremental benefits are 50 avoided infections. Marginal
analysis is similar but refers to a change of just one unit,
say $1 or one infection. Most infection-control programs
would cause incremental changes, not pure marginal
changes.
Infection-Control Investment and Strategies
In the sections that follow, we adopt the perspective of a
hospital administrator and only examine costs and savings
to the hospital. We do not seek to determine a social value
of the health benefits of avoiding hospital-acquired infec-
tion, so the estimate of the benefits of infection control is
conservative. We also assume that all decisions are made
within the short term; this is the time frame in which fixed
costs cannot be changed. The model illustrated in Figure 1
uses hypothetical data to analyze the costs and benefits of
prevention and provides answers to both questions: 1) how
much to invest for infection control and 2) which are the
most appropriate infection-control programs.
How Much To Invest for Infection Control
The horizontal axis in Figure 1 represents an incidence
of wound infections in 50,000 patients undergoing hip
replacement. The vertical axis represents cost and potential
savings. Line A summarizes the relationship between the
cost and the effectiveness of infection control strategies.
To achieve the low incidence of 0.01% requires an invest-
ment of resources in infection control valued at $1.5 mil-
lion. However, to reduce rates to only 5.00% requires a
lesser investment of $393,661. Line B1 represents the
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Figure 1. A model of investment
in infection-control activities. Line
A, cost and effectiveness of
infection control; line B1, gross
costs of infection and benefits of
prevention; line B2, net costs of
infection and benefits of infection
control; line C, total costs; point
X, incidence that minimizes total
costs. 
gross costs of hospital infection, i.e., the gross savings that
would result from prevention. These costs and potential
savings increase with incidence. The primary cost of hos-
pital infection is the loss of bed-days due to prolonged
length of stay. Care must be taken in valuing these bed-
days and other resources used for hospital infection (22).
For economic analysis, consider what else could be done
with the resources released by prevention. A hospital in
which rates of infection are successfully reduced will have
more bed-days available, so new patients can be admitted.
The value of these new admissions to the hospital repre-
sents the gross costs of infection and, therefore, the poten-
tial gross savings from prevention. For example, if demand
for hip replacement is such that patients, their insurers, or
the public medical system is prepared to pay $1,250 to the
hospital for each additional case treated, then the opportu-
nity cost of wound infection is the revenue that could be
earned by treating extra cases with the bed-days used by
hospital infection. In Appendix 1 (available online at:
http://www.cdc.gov/eid/vol10no4/02-0754.htm#app1), we
illustrate how to calculate these costs for an incidence of
10.00% and 5.00%, and these data are used to plot line B1
in Figure 1.
So far we have restricted our discussion of the cost and
savings from prevention to changes in the use of bed-
days. We should also consider the financial expenditures
made by the hospital. The financial expenditures on
resources that represent fixed costs are largely irrelevant,
as they cannot be avoided in the short-term. However,
fixed costs are certainly being used more productively.2
More relevant are the variable or discretionary costs that
change in response to a decrease in the incidence of hos-
pital infection. First, patients who previously would have
stayed for 15 days with a hospital infection now stay only
10 and will incur lower variable costs.3 If the decrease in
variable costs from reducing length of stay by 5 days is
$100 per patient, then line B1 in Figure 1 is too low an
estimate of the costs of infection and the potential savings
from prevention. However, variable costs will also
increase as a result of the increase in patient turnover. At
rates of zero infection, hospitals are treating 2,500 more
patients than before, and this will cause an increase in
variable costs. For example, the capacity to perform the
surgery will have to be increased, requiring more sur-
geons, anesthetists, operating room nurses, and prostheses
and other consumables. If the increase in variable cost is
evaluated at $750 per new admission, then this must be
offset against the $100 per patient reduction in variable
costs and the $1,250 increase in revenue per case. The
result is the net costs of infection and net savings from
prevention. In Appendix 2 (available online at:
http://www.cdc.gov/eid/vol10no4/02-754.htm #app2), we
illustrate how to calculate these costs for an incidence of
10.00% and 5.00%. This suggests that the gross cost of
infection (the gross savings from prevention), marked by
line B1, is incorrect. We indicate the correct values, the
net cost of infection (the net savings from prevention), by
line B2.
Line C in Figure 1 is the total cost to the healthcare sys-
tem and is the sum of lines A and B2 for every incidence
rate of hospital infection. For example, at an incidence of
9.00%, the net cost of infection is $1,582,536 (Line B2),
and the cost of prevention programs is $132,088 (Line A).
The sum of these at an incidence of 9.00% is $1,714,624
(Line C). 
The incidence of infection that minimizes total cost,
indicated by Line C, is marked with an X in Figure 1, and
achieving this incidence represents a rational objective for
policy makers. To explore this point further, consult
Appendix 3 (available online at: http://www.cdc.gov/eid/
vol10no4/02-0754.htm#app3), which includes the values
used to plot lines A, B2, and C between the incidence rates
of 2.9% and 3.4%. We conclude that point X is a rational
policy goal because, at this point, marginal savings exact-
ly compensate the marginal investments in prevention. In
contrast, investments that drive infection rates lower than
point X are not adequately compensated. The data includ-
ed in Appendix 3 show that the last infection we should
prevent will cost $17,810 in terms of infection-control
activities and will release resources worth $17,810.
The investment in prevention that achieves the rate indi-
cated by point X is therefore the correct budget constraint
for infection control. At point X, there is no net gain or loss,
which signals the best achievable, or equilibrium, outcome.
Determining Appropriate Infection-Control Programs
There are many different ways of preventing hospital
infections and therefore many different ways of moving
toward point X. Choices have to be made among the
numerous competing infection-control programs available.
To help make these choices, we apply the technique of
incremental cost-effectiveness analysis (23), where the
costs of the interventions are represented in monetary
terms, and the benefits are measured in natural units com-
mon to all interventions under consideration. For this
example, the benefits of the infection-control programs are
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2At rates of 10% the fixed costs of the organization were used to
treat 50,000 patients, but at zero rates of infection, 52,500 patients
were treated with the same volume of fixed costs; this represents
an improvement in efficiency. See Appendix 1, available online at
http://www.cdc.gov/ncidod/EID/vol10no4/02-0754.htm#app1
3Reductions might be in expenditures on antimicrobials to treat the
infection, the equipment used to deliver therapy, and on resources
used for wound care such as dressings, irrigations, and other con-
sumables. Also, the workload of the nursing staff may be reduced,
so expenditures on agency nurses might be reduced.
the number of cases of infection avoided. We should
choose the infection-control programs that minimize the
cost per infection avoided while remaining within the
budget constraint identified by point X. 
A useful first step is to identify a patient group and an
infection to prevent. Keeping with the example of infec-
tion in hip replacement, the next step is to identify all rea-
sonable strategies that might prevent this type of infection.
In our example, we propose six strategies and assume that
all available prevention strategies are represented by these
six options. The cost, effectiveness, and benefits of each
are illustrated in the Table, and these data are plotted in
Figure 2. Options 1 to 6 compete with each other, and only
the most appropriate will be used.
The status quo is an incidence of 10.00% for a popula-
tion of 50,000 patients who receive a new hip in a given
period. Option 6 is clearly preferable to options 1 to 5
because the cost of preventing one infection by this mode
is only $154, calculated by dividing the cost of option 6 by
the benefit of option 6, both relative to the status quo. This
is an incremental cost-effectiveness ratio (ICER). See
Appendix 4 (available online at: http://www.cdc.gov/eid/
vol10no4/02-0754.htm#app4) to clarify how to calculate
ICERs. In our example, the hospital should first invest
$299,611, moving from the origin to option 6.
Now, all other options (except option 6) are still avail-
able, and any further decisions must be evaluated with
respect to option 6, the new status quo. Both option 1 and
option 3 are less effective and more costly than the status
quo (option 6) and so are excluded. Option 2 beats options
4 and 5; although all prevent further infections, option 2
does so at the lowest cost. The hospital should invest a fur-
ther $343,876, moving from option 6 to option 2. The sta-
tus quo is now option 2, and only options 4 and 5 remain,
with the final move being to option 4. 
The question of which are the most appropriate infec-
tion-control programs has been answered. A policy repre-
sented by a line that joins the origin to the points marked
option 6, option 2, and option 4 illustrates the most appro-
priate, most cost-effective, infection-control strategy.
We have pursued the most cost-effective pathway with-
out considering point X, where total costs to the healthcare
system are minimized. Consider the information included
in Figure 3. This is a version of Figure 1 that includes the
incremental costs and benefits of the six competing strate-
gies described above. The status quo, at an incidence of
10%, and the moves to options 6, 2, and 4 that define the
cost-effective pathway are marked. The figure shows that
the hospital should not invest beyond the point defined by
option 2. While a further move to option 4 is the lowest
cost alternative for preventing further cases of infection,
option 4 exceeds the budget constraint and ultimately
increases costs to the healthcare system (line C).
Discussion
Many have considered the economics of preventing
hospital-acquired infection. We argue, with the exception
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Figure 2. A model of cost, effective-
ness, and benefits of six competing
infection-control strategies. 




of prevention Incremental benefita Effectb 
Option 6 $299,611 1,942 4.00% 
Option 3 $523,487 1,205 2.50% 
Option 2 $643,487 3,346 6.80% 
Option 5 $812,457 3,448 7.10% 
Option 1 $874,512 1,059 2.20% 
Option 4 $892,931 3,960 8.00% 
aCases prevented. 
bReduction in incidence. 
of one study (24), the complexity of the economic issues
has been neglected. In this article we attempt to make the
economics explicit. We demonstrated how the concept of
opportunity cost might be used to value the costs of hospi-
tal infection and therefore the savings from infection con-
trol programs. We argue that existing literature uses
financial costs to represent the cost of infection, and this
method may lead to erroneous conclusions. Financial costs
are a monetized estimate value of health-services cost (25)
and might not satisfy the definition of opportunity cost. We
offer an explicit treatment of how variable costs change in
response to infection control and highlight the difference
between the gross and net costs of hospital infection. We
also suggest that, as the perspective for the analysis broad-
ens, the costs of infection and the potential benefits of
infection control increase. This will affect the position of
point X in our example and, therefore, affect infection con-
trol policy. Finally, we identify a budget constraint for
infection control where the costs of prevention are com-
pensated by simultaneous cost-savings and illustrate how
incremental cost-effectiveness analysis might be used to
identify the most efficient choices for infection control.
To build the model we propose requires data to plot
lines B2 and A; obtaining these data will allow line C to
be estimated and point X to be identified for any given
hospital infection scenario. Plotting line B2 requires data
on the incidence of hospital infection and the resulting
opportunity costs. Although a complicated task, progress
is being made with the specification of models (26,27),
and establishing the true effect of hospital infection on
length of stay and cost is now a more rigorous process.
Deriving values of alternative uses of these bed-days rep-
resents further challenges. Due to the absence of a reliable
market mechanism for health care, finding an accurate
valuation for a marginal admission to a hospital is difficult
(28), as is finding the opportunity cost of bed-days.
Further research in this area is required. Plotting line A
requires that the cost and effectiveness of competing
infection control strategies be understood. Although the
number of economic evaluations that include an assess-
ment of costs and benefits of infection-control strategies
are limited (29), a broad and diverse literature exists on
the effectiveness of many infection-control interventions.
The quality of the evidence is likely to be variable,
encompassing a range between correctly designed, ran-
domized controlled trials and subjective, expert opinion.
If the findings could be synthesized in a rigorous manner,
uncertainty characterized, and summary estimates of the
likely effectiveness derived, the costs of these strategies
could be estimated separately and the data required to plot
line A procured. With data to plot lines A and B2, line C,
and point X can be estimated. Achieving this for the
numerous patient groups and sites of hospital infection
will be a major task, but the conceptual framework,
expertise, and data are available for an explicit treatment
of the economics of preventing hospital infection.
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Figure 3. Six competing infec-
tion-control strategies imposed
on the model of investment in
infection-control activities. 
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